Ardelyx Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.06
Dividend & YieldN/A$ (N/A)
Beta 1.47
Market capitalization 328.06M
Operating cash flow -123.8M
ESG Scores unknown

Company description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -2.73M 4.58M 3.08M -799k
Total Cashflows From Investing Activities -29.89M 23.37M -31.44M 50.95M
Net Borrowings 49.29M -125k -125k -19.44M
Total Cash From Financing Activities 103.55M 155.48M 22.78M 83M
Change To Operating Activities 1.37M -5.93M -7.04M -10.62M
Issuance Of Stock 54.26M 155.48M 22.9M 102.55M
Net Income -91.3M -94.94M -94.31M -158.16M
Change In Cash 3.38M 102.36M -90.1M -18.6M
Effect Of Exchange Rate
Total Cash From Operating Activities -70.27M -76.48M -81.44M -152.55M
Depreciation 2.68M 2.5M 1.82M 1.44M
Change To Account Receivables 10.71M 4.33M 750k -502k
Other Cashflows From Financing Activities
Change To Netincome 8.45M 11.82M 13.36M 15.17M
Capital Expenditures -311k -325k -324k -1.87M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 67.57M 67.57M 60.99M 87.02M
Income Before Tax -91.29M -94.64M -94.31M -158.16M
Net Income -91.3M -94.94M -94.31M -158.16M
Selling General Administrative 23.71M 24.27M 33.15M 72.3M
Gross Profit -67.23M 577k 3.37M 4.98M
Ebit -90.95M -91.26M -90.78M -154.35M
Operating Income -90.95M -91.26M -90.78M -154.35M
Interest Expense -3.53M -5.73M -5.1M -4.5M
Income Tax Expense 4k 303k 2k 4k
Total Revenue 2.61M 5.28M 7.57M 10.1M
Cost Of Revenue 69.84M 4.7M 4.21M 5.12M
Total Other Income ExpenseNet -347k -3.37M -3.53M -3.81M
Net Income From Continuing Ops -91.3M -94.94M -94.31M -158.16M
Net Income Applicable To Common Shares -91.3M -94.94M -94.31M -158.16M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 67.52M 73.13M 75.45M 67.3M
Total Stockholder Equity 115.81M 186.66M 126.11M 82.62M
Other Current Liabilities 963k 6.26M 5.84M 1.3M
Total Assets 183.33M 259.78M 201.56M 149.91M
Common Stock 6k 9k 9k 13k
Other Current Assets
Retained Earnings -365.51M -460.45M -554.76M -712.93M
Treasury Stock -38k 20k -4k -6k
Cash 78.77M 181.13M 91.03M 72.43M
Total Current Liabilities 17.73M 22.22M 28.42M 52.82M
Other Stockholder Equity -38k 20k -4k -6k
Property, Plant, and Equipment 5.61M 7.41M 4.21M 15.11M
Total Current Assets 176.37M 252.06M 194.69M 133.65M
Net Tangible Assets 115.81M 186.66M 126.11M 82.62M
Net Receivables 5.08M 750k 502k
Accounts Payable 1.15M 2.19M 5.63M 4.28M


Insider Transactions

Here are the insider transactions of stock shares related to Ardelyx Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
GRAMMER ELIZABETH ASale at price 1.94 - 1.95 per share.D2022-11-22Officer1.24k
RAAB MICHAEL GSale at price 1.94 - 1.95 per share.D2022-11-22Chief Executive Officer6.22k
ROSENBAUM DAVID PSale at price 1.94 - 1.95 per share.D/I2022-11-22Officer1.95k
RODRIGUEZ SUSANSale at price 1.94 - 1.95 per share.D2022-11-22Officer3.46k
RENZ JUSTIN ASale at price 1.94 - 1.95 per share.D2022-11-22Chief Financial Officer1.5k
BLANKS ROBERTSale at price 1.94 - 1.95 per share.D2022-11-22Officer1.46k
WILLIAMS LAURA A M.D.Sale at price 1.94 - 1.95 per share.D2022-11-22Officer1.24k
MOTT DAVID MPurchase at price 1.22 per share.D2022-11-17Director567k
BLANKS ROBERTSale at price 1.50 per share.D2022-10-05Officer100k
ROSENBAUM DAVID PSale at price 0.92 per share.I2022-09-01Officer3k
GRAMMER ELIZABETH APurchase at price 0.95 per share.D2022-08-31Officer3k
ROSENBAUM DAVID PStock Award(Grant) at price 0.95 per share.I2022-08-31Officer3k
ROSENBAUM DAVID PPurchase at price 0.95 per share.I2022-08-31Officer3k
RENZ JUSTIN AStock Award(Grant) at price 0.95 per share.D2022-08-31Chief Financial Officer3k
RENZ JUSTIN APurchase at price 0.95 per share.D2022-08-31Chief Financial Officer3k
WILLIAMS LAURA A M.D.Stock Award(Grant) at price 0.95 per share.D2022-08-31Officer3k
WILLIAMS LAURA A M.D.Purchase at price 0.95 per share.D2022-08-31Officer3k
FELSCH ROBERT ORA CPAStock Award(Grant) at price 0.95 per share.D2022-08-31Officer3k
FELSCH ROBERT ORA CPAPurchase at price 0.95 per share.D2022-08-31Officer3k
BLANKS ROBERTSale at price 1.04 per share.D2022-08-26Officer21.84k
GRAMMER ELIZABETH ASale at price 0.98 per share.D2022-08-22Officer1.24k
RAAB MICHAEL GSale at price 0.98 per share.D2022-08-22Chief Executive Officer6.15k
ROSENBAUM DAVID PSale at price 0.98 per share.D/I2022-08-22Officer1.96k
RODRIGUEZ SUSANSale at price 0.98 per share.D2022-08-22Officer3.42k
RENZ JUSTIN ASale at price 0.98 per share.D2022-08-22Chief Financial Officer1.5k
BLANKS ROBERTSale at price 0.98 per share.D2022-08-22Officer1.46k
WILLIAMS LAURA A M.D.Sale at price 0.98 per share.D2022-08-22Officer1.28k
BLANKS ROBERTSale at price 0.67 per share.D2022-07-26Officer5.19k
BERTRAND WILLIAM C JRStock Award(Grant) at price 0.00 per share.D2022-06-15Director118.61k
RODGERS RICHARD J.Stock Award(Grant) at price 0.00 per share.D2022-06-15Director132.3k
LUNDBERG JAN MStock Award(Grant) at price 0.00 per share.D2022-06-15Director91.24k
MOTT DAVID MStock Award(Grant) at price 0.00 per share.D2022-06-15Director182.48k
CADORET-MANIER ONAIZAStock Award(Grant) at price 0.00 per share.D2022-06-15Director91.24k
BHANJI MUNAStock Award(Grant) at price 0.00 per share.D2022-06-15Director95.8k
GRAMMER ELIZABETH ASale at price 0.64 - 0.65 per share.D2022-06-06Officer60.82k
RAAB MICHAEL GSale at price 0.64 - 0.65 per share.D2022-06-06Chief Executive Officer103.62k
ROSENBAUM DAVID PSale at price 0.64 - 0.65 per share.D/I2022-06-06Officer61.64k
RODRIGUEZ SUSANSale at price 0.64 - 0.65 per share.D2022-06-06Officer43.92k
RENZ JUSTIN ASale at price 0.64 - 0.65 per share.D2022-06-06Chief Financial Officer73.31k
BLANKS ROBERTSale at price 0.64 - 0.65 per share.D2022-06-06Officer73.31k
GRAMMER ELIZABETH ASale at price 0.67 per share.D2022-05-20Officer1.26k
RAAB MICHAEL GSale at price 0.67 per share.D2022-05-20Chief Executive Officer6.12k
ROSENBAUM DAVID PSale at price 0.67 per share.D/I2022-05-20Chief Technology Officer2.01k
RODRIGUEZ SUSANSale at price 0.67 per share.D2022-05-20Officer3.42k
RENZ JUSTIN ASale at price 0.67 per share.D2022-05-20Chief Financial Officer1.53k
BLANKS ROBERTSale at price 0.67 per share.D2022-05-20Officer1.49k
GRAMMER ELIZABETH ASale at price 0.67 per share.D2022-02-22Officer1.53k
RAAB MICHAEL GSale at price 0.67 per share.D2022-02-22Chief Executive Officer6.23k
ROSENBAUM DAVID PSale at price 0.67 per share.D/I2022-02-22Officer2.35k
RODRIGUEZ SUSANSale at price 0.67 per share.D2022-02-22Officer3.4k
RENZ JUSTIN ASale at price 0.67 per share.D2022-02-22Chief Financial Officer1.8k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Ardelyx Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Ardelyx Inc

Here is the result of two systematic investment strategies applied to Ardelyx Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Ardelyx Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Ardelyx Inc:

Ardelyx Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -71.32% on the backtest period.

Performance at glance

Performance

-71.32 %

Latent gain

-1247.16 $

Invested capital

1748.76 $

Annualized return

-17.4 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Ardelyx Inc

This is the result of two momentum investment strategies applied to Ardelyx Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Ardelyx Inc

The following chart shows all the entries opened by the momentum investment system on Ardelyx Inc:

Ardelyx Inc momentum entries
  • The first momentum investment strategy would give -66.12% of return on Ardelyx Inc. That represents -3970.39$ of latent gain with 6004.39$ of employed capital.
  • The second momentum investment strategy would give -74.6% of return on Ardelyx Inc. That represents -2804.97$ of latent gain with 3760.17$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-66.12 %

Latent gain

-3970.39 $

Invested capital

6004.39 $

Annualized return

-37.5 %
Performance at glance (2Q Momentum)

Performance

-74.6 %

Latent gain

-2804.97 $

Invested capital

3760.17 $

Annualized return

-20.61 %

Momentum equity curve on Ardelyx Inc

The following chart shows the equity curve of the two momentum strategies applied to Ardelyx Inc:

Ardelyx Inc momentum equity

Note: the dividends potentially given by Ardelyx Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Ardelyx Inc

The following chart shows the employed capital evolution of the two momentum strategies on Ardelyx Inc since the beginning:

Ardelyx Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Ardelyx Inc

Buy the dip entry openings on Ardelyx Inc

Ardelyx Inc

The performance achieved by the robo-advisor on Ardelyx Inc is -78.76%. That represents -195.8$ of latent gain with 248.6$ of employed capital. The following chart shows Ardelyx Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Ardelyx Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

-78.76 %

Latent gain

-195.8 $

Invested capital

248.6 $

Annualized return

-37.5 %

Equity curve of the strategy applied to Ardelyx Inc

The following chart shows the result of the investment strategy applied to Ardelyx Inc:

Ardelyx Inc

Note: the dividends potentially given by Ardelyx Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Ardelyx Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Ardelyx Inc:

Ardelyx Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Ardelyx Inc

In this section, I will compare the three previous investment strategies applied to Ardelyx Inc.

Equity curve comparison on Ardelyx Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Ardelyx Inc investment strategy comparison

Employed capital comparison on Ardelyx Inc

Ardelyx Inc investment comparison

Performance comparison on Ardelyx Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -71.32% -1247.16$ 1748.76$ -17.4%
Momentum 1 quarter -66.12% -3970.39$ 6004.39$ -17.13%
Momentum 2 quarters -74.6% -2804.97$ 3760.17$ -20.61%
Non-directional -78.76% -195.8$ 248.6$ -37.5%
Annualized return comparison

Automatic investment

-17.4 %

Momentum 1Q

-20.61 %

Momentum 2Q

-20.61 %

Non-directional

-37.5 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Ardelyx Inc:

Positive correlations

Most correlated stocks this year

  • Ardelyx Inc

  • Most correlated stocks last 3 months

  • Viomi Technology Co Ltd
  • Ardelyx Inc
  • Iamgold Corp
  • WESDOME GOLD MINES LTD.
  • Global X Silver Miners ETF

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between Ardelyx Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Ardelyx Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Ardelyx Inc
    Country United States
    City Waltham
    Address 400 Fifth Avenue
    Phone 510 745 1700
    Website www.ardelyx.com
    FullTime employees 86
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ARDX
    Market www.nasdaq.com

    Ardelyx Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown